Humana Inc. (NYSE:HUM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The brokerage currently has a $273.00 price objective on the insurance provider’s stock. Zacks Investment Research‘s price target points to a potential upside of 10.75% from the company’s current price.

According to Zacks, “Humana is well poised to grow on its strong government business. Its top-line has been witnessing an uptrend from past many years. Sufficient generation of cash flow has helped the company take up several capital deployment initiatives aimed at enhancing shareholders’ value. Humana’s sound balance sheet and disciplined capital management remains a positive.  Following its strong second-quarter 2017 results, it raised its 2017 adjusted EPS guidance. The stock has also seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward in last 30 days. Although the shares have slighly underperformed the industry in past six months, its strong fundamentals are likely to help the stock in gaining momentum going forward.”

Other analysts also recently issued reports about the stock. BidaskClub downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, June 13th. Citigroup Inc. began coverage on shares of Humana in a report on Wednesday, June 28th. They issued a “buy” rating and a $275.00 price target for the company. Credit Suisse Group reissued an “outperform” rating and issued a $260.00 price target (up from $250.00) on shares of Humana in a report on Thursday, August 3rd. Deutsche Bank AG increased their price target on shares of Humana from $234.00 to $243.00 and gave the company a “hold” rating in a report on Monday, August 7th. Finally, Oppenheimer Holdings, Inc. increased their price target on shares of Humana from $236.00 to $255.00 and gave the company an “outperform” rating in a report on Thursday, August 3rd. Nine analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $247.50.

Shares of Humana (HUM) traded down 0.33% during trading on Tuesday, reaching $245.70. 284,924 shares of the company’s stock were exchanged. The firm has a market capitalization of $35.51 billion, a P/E ratio of 20.21 and a beta of 0.86. The company has a 50 day moving average of $249.17 and a 200 day moving average of $234.01. Humana has a 52-week low of $163.50 and a 52-week high of $259.76.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion during the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period in the prior year, the firm earned $2.30 EPS. Equities analysts anticipate that Humana will post $11.55 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Humana Inc. (HUM) Stock Rating Upgraded by Zacks Investment Research” was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/humana-inc-hum-stock-rating-upgraded-by-zacks-investment-research/1610437.html.

In related news, insider William Kevin Fleming sold 3,071 shares of Humana stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the transaction, the insider now owns 7,681 shares of the company’s stock, valued at approximately $1,927,777.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bruce D. Broussard sold 12,000 shares of Humana stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the transaction, the chief executive officer now directly owns 80,086 shares in the company, valued at approximately $20,172,061.68. The disclosure for this sale can be found here. Insiders sold a total of 55,595 shares of company stock worth $14,133,706 in the last ninety days. Insiders own 0.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in HUM. UBS Asset Management Americas Inc. boosted its stake in Humana by 10.6% during the 1st quarter. UBS Asset Management Americas Inc. now owns 458,685 shares of the insurance provider’s stock worth $94,553,000 after acquiring an additional 44,113 shares during the last quarter. Schroder Investment Management Group boosted its stake in Humana by 2.4% during the 1st quarter. Schroder Investment Management Group now owns 34,425 shares of the insurance provider’s stock worth $7,121,000 after acquiring an additional 798 shares during the last quarter. Spark Investment Management LLC bought a new position in Humana during the 1st quarter worth approximately $1,504,000. Suffolk Capital Management LLC bought a new position in Humana during the 1st quarter worth approximately $12,381,000. Finally, BB&T Securities LLC boosted its stake in Humana by 15.0% during the 1st quarter. BB&T Securities LLC now owns 1,751 shares of the insurance provider’s stock worth $360,000 after acquiring an additional 228 shares during the last quarter. 95.12% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.